Answer
Interstitial lung disease or pneumonitis has been reported in clinical trials with Alecensa (alectinib hydrochloride), and patients should be monitored for lung symptoms indicative of pneumonitis.
Sources for this answer
- Alecensa 150 mg Hard CapsulesRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 17Document updated
Sources checked